U.S.-India Trade Framework Signals Major Shift in Tariffs, Energy, and Supply Chains 
Australian Pension Funds Boost Currency Hedging as Aussie Dollar Strengthens 
Asian Stocks Slip as Tech Rout Deepens, Japan Steadies Ahead of Election 
Global Markets Slide as AI, Crypto, and Precious Metals Face Heightened Volatility 
South Africa Eyes ECB Repo Lines as Inflation Eases and Rate Cuts Loom 
Russian Stocks End Mixed as MOEX Index Closes Flat Amid Commodity Strength 
India–U.S. Interim Trade Pact Cuts Auto Tariffs but Leaves Tesla Out 
Nikkei 225 Hits Record High Above 56,000 After Japan Election Boosts Market Confidence 
Australian Household Spending Dips in December as RBA Tightens Policy 
Gold and Silver Prices Rebound After Volatile Week Triggered by Fed Nomination 
Yen Slides as Japan Election Boosts Fiscal Stimulus Expectations 
Japanese Pharmaceutical Stocks Slide as TrumpRx.gov Launch Sparks Market Concerns 
RBI Holds Repo Rate at 5.25% as India’s Growth Outlook Strengthens After U.S. Trade Deal 
Dollar Near Two-Week High as Stock Rout, AI Concerns and Global Events Drive Market Volatility 
UK Starting Salaries See Strongest Growth in 18 Months as Hiring Sentiment Improves 
With zero-duty treatment for flagship products including gems and diamonds, generic drugs, and certain aircraft parts, the new US–India interim trade agreement reduces US tariffs on Indian products from roughly 25% (close 50% effective with punitive levies) to 18%. India promises to raise US imports by USD 500 billion over five years in return, and promises better Indian auto parts access in return for reduced tariffs on American industrial and agricultural products like tree nuts and soybean oil. All things considered, the package redefines a tense tariff scenario beyond 2025, therefore giving Indian exporters renewed pricing power and stability in their most important market.
Following the tariff shock of 2025, zero-duty access re-establishes competitiveness for Surat's diamond polishing and export cluster; jewels and jewellery become front-line champions. Listed companies such Goldiam International and Rajesh Exports have already shown significant stock gains (around 5–20%) on expectation of greater US income; diversified jewellery giants like Titan and Kalyan Jewellers also stand to profit from export-led development. With the 18% tariff limit boosting margins and demand for clothing and shoe exporters such Indo Count, Gokaldas Exports, and Mirza International in their main US markets, textiles and leather follow closely behind.
As zero tariffs on generics and essential ingredients strengthen India's position as the leading supplier to the US under a more fluid Section 232 review and regulatory environment, drugs obtain a structural advantage; Sun Pharma, Dr. Reddy's, and Cipla are set for volume increase. Ancillary industries are also boosted: aircraft and automotive components exemptions support companies including Bharat Forge and Hindustan Aeronautics, whereas chemical and plastics exporters profit from the lowered 18% rate. While politically sensitive industries such dairy and FMCG (e.g., Hatsun Agro) remain shielded from a surge of US imports, keeping local markets fairly insulated, tech and data-center participants like Netweb and E2E Networks may ride growing GPU and trade flows.
